{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Needham EJ"],"funding":["Brain Research UK","European Research Council","Medical Research Council","National Institute for Health Research (NIHR)","Rosetrees","Wellcome Trust","Academy of Medical Sciences"],"pagination":["90-100"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616895"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["207(1)"],"pubmed_abstract":["Most of the variation in outcome following severe traumatic brain injury (TBI) remains unexplained by currently recognized prognostic factors. Neuroinflammation may account for some of this difference. We hypothesized that TBI generated variable autoantibody responses between individuals that would contribute to outcome. We developed a custom protein microarray to detect autoantibodies to both CNS and systemic Ags in serum from the acute-phase (the first 7 d), late (6-12 mo), and long-term (6-13 y) intervals after TBI in human patients. We identified two distinct patterns of immune response to TBI. The first was a broad response to the majority of Ags tested, predominantly IgM mediated in the acute phase, then IgG dominant at late and long-term time points. The second was responses to spec"],"journal":["Journal of immunology (Baltimore, Md. : 1950)"],"pubmed_title":["Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury."],"pmcid":["PMC7616895"],"funding_grant_id":["MR/R005036/1","AMS-CSF4-Newcombe","M589","UKDRI-1003","ACF-2006-14-004","720931","G0802251","ACF-2009-14-007","RG79413","CSF004\\1002","681712","105924/Z/14/Z","201819-20","105924"],"pubmed_authors":["Needham EJ","Zanier ER","Outtrim JG","Menon DK","Thelin EP","Helmy AE","Taussig MJ","Newcombe VFJ","Simren J","Wang KKW","Jones JL","Piehl F","Coles AJ","Zetterberg H","Hutchinson PJ","Ashton NJ","Yang Z","Stoevesandt O","Al Nimer F","Mousa HS","Blennow K"],"additional_accession":[]},"is_claimable":false,"name":"Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury.","description":"Most of the variation in outcome following severe traumatic brain injury (TBI) remains unexplained by currently recognized prognostic factors. Neuroinflammation may account for some of this difference. We hypothesized that TBI generated variable autoantibody responses between individuals that would contribute to outcome. We developed a custom protein microarray to detect autoantibodies to both CNS and systemic Ags in serum from the acute-phase (the first 7 d), late (6-12 mo), and long-term (6-13 y) intervals after TBI in human patients. We identified two distinct patterns of immune response to TBI. The first was a broad response to the majority of Ags tested, predominantly IgM mediated in the acute phase, then IgG dominant at late and long-term time points. The second was responses to spec","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-21T21:50:20.032Z","creation":"2025-04-21T21:50:20.032Z"},"accession":"S-EPMC7616895","cross_references":{"pubmed":["34145056"],"doi":["10.4049/jimmunol.2001309"]}}